Halozyme Therapeutics, Inc. (HALO)

Market Cap	5.74B
Revenue (ttm)	947.36M
Net Income (ttm)	392.47M
Shares Out	127.23M
EPS (ttm)	3.02
PE Ratio	15.14
Forward PE	9.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	208,683
Open	45.85
Previous Close	45.76
Day's Range	44.82 - 46.01
52-Week Range	33.15 - 65.53
Beta	1.29
Analysts	Buy
Price Target	61.11 (+35.47%)
Earnings Date	Oct 31, 2024

About HALO

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 373
• Stock Exchange: NASDAQ
• Ticker Symbol: HALO
• Website: https://halozyme.com

Financial Performance

In 2023, Halozyme Therapeutics's revenue was $829.25 million, an increase of 25.62% compared to the previous year's $660.12 million. Earnings were $281.59 million, an increase of 39.31%.

Analyst Forecast

According to 9 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $61.11, which is an increase of 35.47% from the latest price.

Price Target

$61.11

(35.47% upside)

Analyst Consensus: Buy